Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

References

Page 1

	Year	Citations
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN A. Mahgoub, L. G. Dring, Jeffrey R. Idle, The Lancet Bioorganic ChemistryBiochemistryMedicineNatural SciencesToxicology	1977	1.2K
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Frank J. Gonzalez, Radek C. Skodat, Shioko Kimura, Nature BiologyMendelian DisorderGenetic DisorderGeneticsInherited Metabolic Disease	1988	715
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. David A. Evans, A. Mahgoub, T.P. Sloan, Journal of Medical Genetics GeneticsGenetic EpidemiologyHuman PolymorphismMendelian DisorderToxicology	1980	540
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man A. K�pfer, R Preisig European Journal of Clinical Pharmacology PharmacologyPharmacogenomicsMedicine	1984	363
High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver Thomas Kronbach, Daniel Mathys, Josef Gut, Analytical Biochemistry Health SciencesBiochemistryMedicineLiver PhysiologyBioanalysis	1987	262
Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs S V Otton, T. Inaba, W. Kalow Life Sciences Molecular PharmacologySparteine OxidationMedicineLiver PhysiologyPhysiology	1984	187
Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation Peter J. Meier, Heinz K. Mueller, Bernhard Dick, Gastroenterology Redox BiologyOxidative StressToxicologyHepatotoxicityDrug Oxidation	1983	123
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers T. Leemann, Pierre Dayer, Urs Meyer European Journal of Clinical Pharmacology Medicinal ChemistryPharmaceutical ScienceBiochemistryMedicineNatural Sciences	1986	112
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Gut, Therese Catin, Pierre Dayer, Journal of Biological Chemistry Secondary MetaboliteDebrisoquine/sparteine-type PolymorphismRedox BiologyToxicological MechanismMolecular Pharmacology	1986	111
Evidence for an enzymatic defect in the 4‐hydroxylation of debrisoquine by human liver. DS Davies, GC Kahn, Sandra Murray, British Journal of Clinical Pharmacology HepatologyBiochemistryMedicineLiver PhysiologyBioanalysis	1981	93

Page 1